A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Clinical Trials, High Risk Prostate Cancer, Intermediate Risk Prostate Cancer

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT06257264
Phase: PHASE1
Trial Summary: This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and pre – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): BeiGene
Acronym:

Pin It on Pinterest